71 related articles for article (PubMed ID: 38616252)
41. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
[TBL] [Abstract][Full Text] [Related]
42. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.
Klempner SJ; Aubin G; Dash A; Ou SH
Oncologist; 2014 Sep; 19(9):1008-10. PubMed ID: 25096999
[TBL] [Abstract][Full Text] [Related]
43. Crizotinib: A comprehensive review.
Sahu A; Prabhash K; Noronha V; Joshi A; Desai S
South Asian J Cancer; 2013 Apr; 2(2):91-7. PubMed ID: 24455567
[TBL] [Abstract][Full Text] [Related]
44. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Shaw AT; Kim DW; Nakagawa K; Seto T; Crinó L; Ahn MJ; De Pas T; Besse B; Solomon BJ; Blackhall F; Wu YL; Thomas M; O'Byrne KJ; Moro-Sibilot D; Camidge DR; Mok T; Hirsh V; Riely GJ; Iyer S; Tassell V; Polli A; Wilner KD; Jänne PA
N Engl J Med; 2013 Jun; 368(25):2385-94. PubMed ID: 23724913
[TBL] [Abstract][Full Text] [Related]
45. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Cui JJ; Tran-Dubé M; Shen H; Nambu M; Kung PP; Pairish M; Jia L; Meng J; Funk L; Botrous I; McTigue M; Grodsky N; Ryan K; Padrique E; Alton G; Timofeevski S; Yamazaki S; Li Q; Zou H; Christensen J; Mroczkowski B; Bender S; Kania RS; Edwards MP
J Med Chem; 2011 Sep; 54(18):6342-63. PubMed ID: 21812414
[TBL] [Abstract][Full Text] [Related]
46. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
47. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
Solomon B; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2009 Dec; 4(12):1450-4. PubMed ID: 20009909
[TBL] [Abstract][Full Text] [Related]
48. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
[TBL] [Abstract][Full Text] [Related]
49. How I do it: evaluating renal masses.
Israel GM; Bosniak MA
Radiology; 2005 Aug; 236(2):441-50. PubMed ID: 16040900
[TBL] [Abstract][Full Text] [Related]
50. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).
Felip E; Stahel RA; Pavlidis N;
Ann Oncol; 2005; 16 Suppl 1():i28-9. PubMed ID: 15888743
[No Abstract] [Full Text] [Related]
51. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma.
Konda R; Sato H; Hatafuku F; Nozawa T; Ioritani N; Fujioka T
J Urol; 2004 Jun; 171(6 Pt 1):2166-70. PubMed ID: 15126778
[TBL] [Abstract][Full Text] [Related]
52. Mediation of renal cyst formation by hepatocyte growth factor.
Horie S; Higashihara E; Nutahara K; Mikami Y; Okubo A; Kano M; Kawabe K
Lancet; 1994 Sep; 344(8925):789-91. PubMed ID: 7916076
[TBL] [Abstract][Full Text] [Related]
53. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
55. Canadian perspectives: update on inhibition of
Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
[TBL] [Abstract][Full Text] [Related]
56. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
57. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
58. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
59. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
60. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]